Paolo Springhetti

#EHJCVI 💡 What are the sex differences in the evolution and outcomes of mild–moderate AS with pLVEF? 📌 Men: faster rise in peak velocity and mean gradient 📌 Women: more concentric LV remodelling, hypertrophy, and declining SV 📚 Dive into the data 👉 doi.org/10.1093/ehjci/…

Happy to share our research! In mild-to-moderate AS with preserved LVEF, men show faster progression in gradients, while women develop more concentric LV remodeling and reduced stroke volume over time, potentially masking AS progression. @ClavelLabo academic.oup.com/ehjcimaging/ad…

This comprehensive review examined the durability of TAVI compared to SAVR, addressing definitions, mechanisms, and long-term data on bioprosthetic valve dysfunction and failure. While midterm outcomes are comparable, long-term durability remains to be fully established. @TernacleJ @PPibarot ow.ly/uXZS50SBTC9 #Cardiology #MedicalResearch #TAVI #SAVR #HealthcareInnovation

🔥🔥

The flow knows - Severe MR in paradoxical LFLGAS is associated with worse outcomes. AVR may improve survival—hemodynamic assessment by echo is key! @ShaniDahanMD @JudyHungMD @MghHeartHealth #AHAJournals ahajrnls.org/42e9qgm

3D echo improves TR severity grading vs. 2D, closely matching CMR. A new 5-class CMR grading scheme enhances multimodality assessment! @DoldiP #AHAJournals ahajrnls.org/4hQ2USN

And here are finally the 5-year results of Evolut Low Risk, a trial in which the self-expanding prosthesis holds its own against surgery. A trial where, let’s remember, the average age was 74 years. For years, to the question: 'How long does a TAVI prosthesis last?' we didn’t know what to answer. Now I think we can say with certainty: 'At least 5 years.' Still too early to claim victory, but not the disaster that some predicted years ago either. #ACC25 jacc.org/doi/10.1016/j.…

Incidence and Impact of Structural Valve Deterioration Following #TAVI: a Multicenter Real-World Study ➡️ In this real-world registry, the incidence of SVD at 8-years after TAVI was relatively low ➡️ academic.oup.com/ehjcimaging/ad… @ESC_Journals @bernhard_gerber @DonalErwan @JGrapsa

The rise of CIED-related TR demands awareness, better screening, and refined interventional strategies. A must-read perspective by M. Andreas, Philipp E. Bartko, @AndreasZirlik et al. 📖 ow.ly/7UQb50VfCHs #CIED #TricuspidRegurgitation #StructuralHeart #TTVR #TTEER

The role of Transaortic Flow Rate in stratifying prognosis in patients with moderate AS! @JournalASEcho onlinejase.com/article/S0894-… @michetomaselli @lpbadano @GiovanniBenfari @denisamuraru @MdScarsini @noela_radu @MdLPortolan @ClementA25 @TwittAuxologico

Sex-related differences in prosthesis-patient mismatch after surgical aortic valve replacement and long-term outcomes. Read more in #EHJ 👉 ow.ly/3ylC50V3n3k @RoccoMontone @ehj_ed #SAVR

#PPhilippe (editor-in-chief) presents the #JHVS, fully dedicated to heart valve disease, and which aims to advance understanding and improve patient outcomes by publishing high-quality research across diverse disciplines, from basic science to patient advocacy. Read more here👇 journals.sagepub.com/doi/full/10.11…

After 3 years of relentless hard work, passion, and dedication to #cvimaging and research in TR, our brilliant PhD student @michetomaselli has successfully defended his thesis! Michele, your fantastic journey has been inspiring for so many fellows and researchers that had the chance to work with you. The future is bright, and I’m honored to have been part of your path and to work with you daily. Congratulations—this is just the beginning! @lpbadano @ClementA25 @giorgio_oliver @Fraheilbron @Springhetti_P @fpperelli @GParati22 @TwittAuxologico @unimib #3DEcho #PhDSuccess #TricuspidRegurgitation #ProudMentor #FutureLeader

Transapical #TMVR after ELASTA-Clip is a feasible and less invasive option for the management of failed M-TEER that can be performed with acceptable results in a carefully selected patient population. jacc.org/doi/10.1016/j.… #JACCINT #cvSurg #TEER @FabienPraz @DaryoushSamim

We are thrilled to share our latest original paper, published in the prestigious European Heart Journal! A big thank you to @ClavelLabo for her far-sighted and invaluable mentorship! @PPibarot academic.oup.com/eurheartj/adva…

T-TEER improves 1-year survival in patients with intermediate-stage tricuspid regurgitation💡 No benefit seen in early or advanced stages 🚑 Timing of intervention is crucial for optimal outcomes! 🫀 jacc.org/doi/10.1016/j.… #TEER #Cardiology #vhdTR @PhilippLurz

Mortality associated with moderate and severe mitral regurgitation in 608 570 men and women undergoing echocardiography bit.ly/3VSS7zg

Yearly incidence of CE after #TAVR is low. In the event of CE, pts who have not undergone #PCI have a worse outcome. SEV pts have a higher rate of unfavorable outcomes & are less likely to undergo PCI, especially when admitted to non-TAVR centers jacc.org/doi/10.1016/j.… #JACCINT

Congratulations! Happy to be involved with our team in this nice project. Thank you all for the great collaboration to an important paper. @lpbadano @michetomaselli @denisamuraru @Springhetti_P

Check out our latest paper pubblished on the Canadian Journal of Cardiology🔥we identified outcome-based cutoffs for both corrected EROA and 3D-derived RV volumes, RVEF and RV-to-PA coupling!The framework among these parameters is complex! onlinecjc.ca/article/S0828-…